Trials / Completed
CompletedNCT02011945
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination Dasatinib (BMS-354825) Plus Nivolumab (BMS-936558) in Patients Chronic Myeloid Leukemia (CML)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib | |
| DRUG | Nivolumab |
Timeline
- Start date
- 2014-02-07
- Primary completion
- 2018-12-26
- Completion
- 2018-12-26
- First posted
- 2013-12-16
- Last updated
- 2020-03-18
- Results posted
- 2019-01-17
Locations
21 sites across 7 countries: United States, Australia, Canada, France, Germany, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02011945. Inclusion in this directory is not an endorsement.